Perrigo Company plc (PRGO) has received final approval from the U.S. Food & Drug Administration or FDA for its abbreviated new drug application or ANDA for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets and has commenced shipment of product. Earlier, Perrigo launched the 0.5 mg strength in 2013.
Prandin tablets, are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus and have annual sales of some $250 million, as measured by Symphony Health Solutions.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.